Brief: Vir Biotechnology Q2 EPS USD 0.48
05/08/2026 21:06
BRIEF-Vir Biotechnology Q2 EPS USD 0.48 Aug 05 (Reuters) - Vir Biotechnology Q2 revenue USD 238.9 million vs. IBES estimate USD 216.5 million.
- Q2 net income USD 80.1 million
Recent news on Vir Biotechnology
See all newsVir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead
Brief: Vir Biotechnology Announces Psma-Targeted Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 Received FDA Fast Track Designation For The Treatment Of Prostate Cancer
Brief: Vir Biotechnology Appoints David Liu As Chief Medical Officer
Vir Biotechnology rises after naming Theravance's Sawaf as CFO